MCKESSON CORP Form 10-Q January 27, 2016 Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

(Mark One)

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2015

0 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to Commission File Number: 1-13252

McKESSON CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	94-3207296
(State or other jurisdiction	(I.R.S. Employer
of incorporation or organization)	Identification No.)
One Post Street, San Francisco, California	94104
(Address of principal executive offices)	(Zip Code)
(415) 983-8300	
(Registrant's telephone number, including area code)	

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (\$232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. Large accelerated filer x Accelerated filer o

 Non-accelerated filer
 o (Do not check if a smaller reporting company)
 Smaller reporting company o

 Indicate by check mark
 whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
 O (Do not check if a smaller reporting company o

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. Class Outstanding as of December 31, 2015

Common stock, \$0.01 par value

Outstanding as of 228,586,974 shares

Table of Contents McKESSON CORPORATION

TABLE OF CONTENTS

	Item	Page
	PART I—FINANCIAL INFORMATION	
1.	Condensed Consolidated Financial Statements	
	Condensed Consolidated Statements of Operations for the Quarters and Nine Months Ended December 31, 2015 and 2014	<u>3</u>
	Condensed Consolidated Statements of Comprehensive Income (Loss) for the Quarters and Nine Months Ended December 31, 2015 and 2014	<u>4</u>
	Condensed Consolidated Balance Sheets as of December 31, 2015 and March 31, 2015	<u>5</u>
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended December 31, 2015 and 2014	<u>6</u>
	Financial Notes	7
2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>25</u>
3.	Quantitative and Qualitative Disclosures About Market Risk	<u>39</u>
4.	Controls and Procedures	<u>39</u>
	PART II—OTHER INFORMATION	
1.	Legal Proceedings	<u>39</u>
1A.	Risk Factors	<u>39</u>
2.	Unregistered Sales of Equity Securities and Use of Proceeds	<u>39</u>
3.	Defaults Upon Senior Securities	<u>40</u>
4.	Mine Safety Disclosures	<u>40</u>
5.	Other Information	<u>40</u>
6.	Exhibits	<u>41</u>
	Signatures	<u>42</u>

<u>Table of Contents</u> McKESSON CORPORATION

PART I—FINANCIAL INFORMATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In millions, except per share amounts) (Unaudited)

	Quarter Ended December 31,				Nine Months Ended December 31,			
	2015 2014				2015	2014		
Revenues	\$47,899		\$46,484		\$144,20	6	\$134,12	20
Cost of Sales	(45,027		(43,586)	(135,642		(125,62	
Gross Profit	2,872		2,898		8,564		8,494	/
Operating Expenses	(1,952)	(2,098)	(5,759)	(6,226)
Operating Income	920		800	ĺ	2,805		2,268	
Other Income, Net	13		12		43		53	
Interest Expense	(87)	(93)	(267)	(284)
Income from Continuing Operations Before Income Taxes	846		719		2,581		2,037	
Income Tax Expense	(204)	(198)	(704)	(606)
Income from Continuing Operations	642		521		1,877		1,431	
Income (Loss) from Discontinued Operations, Net of Tax	5		(10)	(11)	(32)
Net Income	647		511		1,866		1,399	
Net Income Attributable to Noncontrolling Interests	(13)	(39)	(39)	(55)
Net Income Attributable to McKesson Corporation	\$634		\$472		\$1,827		\$1,344	
Earnings (Loss) Per Common Share Attributable to McKesson Corporation Diluted								
Continuing operations	\$2.71		\$2.04		\$7.86		\$5.85	
Discontinued operations	0.02		(0.04)	(0.05)	(0.13)
Total	\$2.73		\$2.00	,	\$7.81	,	\$5.72	,
Basic	,							
Continuing operations	\$2.74		\$2.07		\$7.95		\$5.94	
Discontinued operations	0.02		(0.04)	(0.04)	(0.14)
Total	\$2.76		\$2.03	ĺ	\$7.91	í	\$5.80	
Dividends Declared Per Common Share	\$0.28		\$0.24		\$0.80		\$0.72	
Weighted Average Common Shares Diluted	232		236		234		235	
Basic	232		230		234		233 232	
	200				<i></i> 1			

See Financial Notes

3

Table of Contents McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (In millions)

(Unaudited)

	Quarter Ended December 31,		Nine Months Ende December 31,			
Net Income	2015 \$647	2014 \$511	2015 \$1,866	2014 \$1,399		
Other Comprehensive Income (Loss), Net of Tax Foreign currency translation adjustments arising during period	(246) (416) (142)	(995))	
Unrealized gains (losses) on cash flow hedges arising during period	(1) 1	5	(1))	
Retirement-related benefit plans Other Comprehensive Income (Loss), Net of Tax	15 (232	•	, . , , ,	(8) (1,004)))	
Comprehensive Income (Loss) Comprehensive Loss (Income) Attributable to Noncontrolling Interests Comprehensive Income (Loss) Attributable to McKesson Corporation		80 13 \$93	1,727 (32) \$1,695	395 148 \$543		

See Financial Notes

4

Table of Contents McKESSON CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In millions, except per share amounts) (Unaudited)

(Unaudited)	December 31, 2015	March 31, 2015
ASSETS		
Current Assets		
Cash and cash equivalents	\$3,406	\$5,341
Receivables, net	17,402	15,914
Inventories, net	16,411	14,296
Prepaid expenses and other	1,042	1,119
Total Current Assets	38,261	36,670
Property, Plant and Equipment, Net	2,112	2,045
Goodwill	9,701	9,817
Intangible Assets, Net	3,103	3,441
Other Assets	1,910	1,897
Total Assets	\$55,087	\$53,870
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY		
Current Liabilities		
Drafts and accounts payable	\$26,854	\$25,166
Short-term borrowings	7	135
Deferred revenue	999	1,078
Deferred tax liabilities	1,979	1,820
Current portion of long-term debt	996	1,529
Other accrued liabilities	3,644	3,769
Total Current Liabilities	34,479	33,497
Long-Term Debt	7,715	8,180
Other Noncurrent Liabilities	2,555	2,722
Commitments and Contingent Liabilities (Note 13)		
Redeemable Noncontrolling Interests	1,378	1,386
McKesson Corporation Stockholders' Equity		
Preferred stock, \$0.01 par value, 100 shares authorized, no shares issued or		
outstanding		
Common stock, \$0.01 par value, 800 shares authorized at December 31, 2015 and	1	
March 31, 2015, 271 and 384 shares issued at December 31, 2015 and	3	4
March 31, 2015		
Additional Paid-in Capital	5,793	6,968
Retained Earnings	7,995	12,705
Accumulated Other Comprehensive Loss	(1,845)	(1,713
Other	(2)	(7
Treasury Shares, at Cost, 42 and 152 at December 31, 2015 and March 31, 2015	(3,068)	(9,956
Total McKesson Corporation Stockholders' Equity	8,876	8,001
Noncontrolling Interests	84	84
Total Equity	8,960	8,085
Total Liabilities, Redeemable Noncontrolling Interests and Equity	\$55,087	\$53,870

))))

See Financial Notes

5

Table of Contents McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

(Unaudited)

(Unaudited)				
	Nine Months Ended December 31,			
	2015		2014	
Operating Activities				
Net income	\$1,866		\$1,399	
Adjustments to reconcile to net cash provided by operating activities:				
Depreciation and amortization	671		786	
Deferred taxes	30		74	
Charges associated with last-in-first-out inventory method	215		287	
Share-based compensation expense	113		127	
Gain from sales of businesses	(103)		
Other non-cash items	139	,	(51)
Changes in operating assets and liabilities, net of acquisitions:				<i>,</i>
Receivables	(1,667)	(2,815)
Inventories	(2,397	ý	(2,580)
Drafts and accounts payable	1,695	,	4,074	/
Deferred revenue	(66)	(19)
Taxes	114	,	(203)
Other	(44)	150	,
Net cash provided by operating activities	566	,	1,229	
The cush provided by operating activities	200		1,222	
Investing Activities				
Property acquisitions	(272)	(281)
Capitalized software expenditures	(145	ý	(118	ý
Acquisitions, net of cash and cash equivalents acquired	(25))	(40	
Proceeds from sale of businesses, net	204)	15)
Other	10		(15)
Net cash used in investing activities	(228)	(439)
The cush used in investing derivities	(220)	(15))
Financing Activities				
Proceeds from short-term borrowings	1,532		2,424	
Repayments of short-term borrowings	(1,668)	(2,320)
Proceeds from issuances of long-term debt		,	3)
Repayments of long-term debt	(996)	(233)
Common stock transactions:	())0)	(235)
Issuances	97		115	
Share repurchases, including shares surrendered for tax withholding	(960)	(106)
Dividends paid	(179		(100)	
Other	(73		36)
Net cash used in financing activities	(2,247)	(252)
Effect of exchange rate changes on cash and cash equivalents))
Net increase (decrease) in cash and cash equivalents	(26 (1,935)	(144 394)
Cash and cash equivalents at beginning of period	-)		
	5,341 \$ 2,406		4,193 \$ 4,587	
Cash and cash equivalents at end of period	\$3,406		\$4,587	

See Financial Notes

Table of Contents McKESSON CORPORATION FINANCIAL REVIEW (UNAUDITED)

1. Significant Accounting Policies

Basis of Presentation: The condensed consolidated financial statements of McKesson Corporation ("McKesson," the "Company," or "we" and other similar pronouns) include the financial statements of all wholly-owned subsidiaries and majority owned or controlled companies. We also evaluate our ownership, contractual and other interests in entities to determine if they are variable interest entities ("VIEs"), if we have a variable interest in those entities and the nature and extent of those variable interests. These evaluations are highly complex and involve judgment and the use of estimates and assumptions based on available historical information and management's judgment, among other factors. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method and our proportionate share of income or loss is recorded in Other Income, Net. Intercompany transactions and balances have been eliminated. The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and, therefore, do not include all information and disclosures normally included in the annual consolidated financial statements.

To prepare the financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts may differ from these estimated amounts. In our opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods presented.

The results of operations for the quarter and nine months ended December 31, 2015 are not necessarily indicative of the results that may be expected for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies and financial notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015 previously filed with the SEC on May 12, 2015 ("2015 Annual Report").

Certain prior period amounts, which relate to our discontinued operations, have been reclassified to conform to the current period presentation.

The Company's fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company's fiscal year.

Recently Adopted Accounting Pronouncements

Discontinued Operations: In the first quarter of 2016, we adopted amended guidance for reporting of discontinued operations and disclosures of disposals of components. The amended guidance revises the criteria for disposals to qualify as discontinued operations and permits significant continuing involvement and continuing cash flows with the discontinued operation. In addition, the amended guidance requires additional disclosures for discontinued operations and new disclosures for individually material disposal transactions that do not meet the definition of a discontinued operation. Refer to Financial Notes 4 and 5, "Divestiture of Businesses" and "Discontinued Operations," for more information regarding the impact of this amended guidance on our condensed consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted

Financial Instruments: In January 2016, amended guidance was issued that requires equity investments to be measured at fair value with changes in fair value recognized in net income and enhanced disclosures about those investments. This guidance also simplifies the impairment assessments of equity investments without readily determinable fair value. The investments that are accounted for under the equity method of accounting or result in consolidation of the investee are excluded from the scope of this amended guidance. The amended guidance will become effective for us

commencing in the first quarter of 2019 and will be adopted through a cumulative-effect adjustment. Early adoption is not permitted except for certain provisions. We are currently evaluating the impact of this amended guidance on our consolidated financial statements.

7

Deferred Income Taxes: In November 2015, amended guidance was issued for the balance sheet classification of deferred income taxes. The amended guidance requires the classification of all deferred tax assets and liabilities as noncurrent on the balance sheet instead of separating deferred taxes into current and noncurrent amounts. Deferred tax assets and liabilities will continue to be offset and presented as a single amount under the amended guidance. The amended guidance will become effective for us commencing in the first quarter of 2018 and will only result in a change in presentation of these deferred taxes on our consolidated balance sheets. The amended guidance can be adopted either on a prospective or retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Business Combinations: In September 2015, amended guidance was issued for an acquirer's accounting for measurement-period adjustments. The amended guidance eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments retrospectively and instead requires that measurement-period adjustments be recognized during the period in which it determines the adjustment. In addition, the amended guidance requires that the acquirer record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The amended guidance is effective for us prospectively commencing in the first quarter of 2017. Early adoption is permitted. Inventory: In July 2015, amended guidance was issued for the subsequent measurement of inventory. The amended guidance requires entities to measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The requirement would replace the current lower of cost or market evaluation. Accounting guidance is unchanged for inventory measured using last-in, first-out ("LIFO") or the retail method. The amended guidance will become effective for us commencing in the first quarter of 2018. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements. Fair Value Measurement: In May 2015, amended guidance was issued that limits disclosures and removes the requirement to categorize investments within the fair value hierarchy if the fair value of the investment is measured using the net asset value per share practical expedient. The amended guidance will become effective for us retrospectively commencing in the first quarter of 2017. Early adoption is permitted. This amended guidance is primarily expected to affect our annual disclosures related to our pension benefits. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Fees Paid in a Cloud Computing Arrangement: In April 2015, amended guidance was issued for a customer's accounting for fees paid in a cloud computing arrangement. The amended guidance requires customers to determine whether or not an arrangement contains a software license element. If the arrangement contains a software element, the related fees paid should be accounted for as an acquisition of a software license. If the arrangement does not contain a software license, it is accounted for as a service contract. The amended guidance will become effective for us commencing in the first quarter of 2017. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Debt Issuance Costs: In April 2015, amended guidance was issued for the balance sheet presentation of debt issuance costs. The amended guidance requires debt issuance costs related to a recognized debt liability to be reported on the balance sheet as a direct deduction from the carrying amount of that debt liability. The recognition and measurement guidance for debt issuance costs is not affected by the amended guidance. In August 2015, a clarification was added to this amended guidance that debt issuance costs related to line-of-credit arrangements can continue to be deferred and presented as an asset on the balance sheet. The amended guidance will become effective for us commencing in the first quarter of 2017. Early adoption is permitted. The amended guidance will affect financial statement presentation only and therefore we do not expect the adoption of this guidance to have a material effect on our condensed consolidated financial statements.

Consolidation: In February 2015, amended guidance was issued for consolidating legal entities in which a reporting entity holds a variable interest. The amended guidance modifies the evaluation of whether limited partnerships and similar legal entities are VIEs and changes the consolidation analysis of reporting entities that are involved with VIEs that have fee arrangements and related party relationships. The amended guidance will become effective for us commencing in the first quarter of 2017. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

<u>Table of Contents</u> McKESSON CORPORATION FINANCIAL NOTES (CONTINUED) (UNAUDITED)

Revenue Recognition: In May 2014, amended guidance was issued for recognizing revenue from contracts with customers. The amended guidance eliminates industry specific guidance and applies to all companies. Revenues will be recognized when an entity satisfies a performance obligation by transferring control of a promised good or service to a customer in an amount that reflects the consideration to which the entity expects to be entitled for that good or service. Revenue from a contract that contains multiple performance obligations is allocated to each performance obligation generally on a relative standalone selling price basis. The amended guidance also requires additional quantitative and qualitative disclosures. In August 2015, additional guidance was issued to defer the effective date of the amended revenue recognition guidance by one year. As a result, the amended guidance is effective for us commencing in the first quarter of 2019. The amended guidance allows for either full retrospective adoption or modified retrospective adoption. Early adoption is permitted but not prior to our first quarter of 2018. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements. 2. Business Combinations

In September 2015, we entered into an agreement to acquire the pharmaceutical distribution business of UDG Healthcare Plc ("UDG") based in Ireland for €408 million in cash (or, using the currency exchange ratio of \$1.09/€1 as of December 31, 2015, approximately \$445 million). The business primarily provides pharmaceutical and other healthcare products to retail and hospital pharmacies. The transaction was approved by UDG shareholders on October 13, 2015, and is subject to the approval of the applicable regulatory authorities as well as other customary closing conditions. The acquisition is currently expected to close during the first half of calendar year 2016. In July 2015, we announced plans to acquire the pharmacy business of J Sainsbury Plc ("Sainsbury") based in the U.K. for £125 million in cash (or, using the currency exchange ratio of \$1.48/£1 as of December 31, 2015, approximately \$185 million). Under the terms of the transaction, we will acquire 281 pharmacies in the U.K. including 277 in-store pharmacies and four hospital pharmacies. The transaction is subject to the approval of the applicable regulatory authorities as well as other customary closing conditions and is currently expected to close during the first half of calendar year 2016.

Upon closing, the acquired UDG and Sainsbury businesses will be included as part of our International pharmaceutical distribution and services business within our Distribution Solutions segment.

We completed a number of smaller acquisitions within our Distribution Solutions segment during the last two years. Financial results for our business acquisitions have been included in our consolidated financial statements since their respective acquisition dates. Purchase prices for our business acquisitions have been allocated based on estimated fair values at the date of acquisition. Goodwill recognized for our business acquisitions is generally not expected to be deductible for tax purposes. However, if we acquire the assets of a company, the goodwill may be deductible for tax purposes.

3. Redeemable Noncontrolling Interests

Under a domination and profit and loss transfer agreement (the "Domination Agreement"), McKesson is obligated to pay an annual recurring compensation amount of €0.83 per Celesio share ("Compensation Amount") to the noncontrolling shareholders of Celesio AG ("Celesio"). Additionally, the noncontrolling interests in Celesio are redeemable at the option of the holder as a result of a right to put their Celesio shares at €22.99 per share ("Put Right") under the Domination Agreement. Accordingly, the noncontrolling interests in Celesio are presented as "Redeemable Noncontrolling Interests" on the accompanying condensed consolidated balance sheet. The Put Right amount is increased annually for interest in the amount of five percentage points above a base rate published by the German Bundesbank semiannually, less the guaranteed dividend paid during the second quarter of 2016 related to calendar year 2014 ("Guaranteed Dividend") and any Compensation Amount already paid in respect of the relevant time period ("Put Amount"). The Domination Agreement was approved at the general shareholders' meeting of Celesio on July 15, 2014, approved by the Stuttgart Higher Regional Court for registration on December 2, 2014.

<u>Table of Contents</u> McKESSON CORPORATION FINANCIAL NOTES (CONTINUED) (UNAUDITED)

Subsequent to the Domination Agreement's registration, certain noncontrolling shareholders of Celesio initiated appraisal proceedings ("Appraisal Proceedings") with the Stuttgart Higher Regional Court to challenge the Compensation Amount, Guaranteed Dividend and/or Put Amount. As long as any Appraisal Proceedings are pending, the Compensation Amount, Guaranteed Dividend and/or Put Amount will be paid as specified currently in the Domination Agreement. If any such Appraisal Proceedings result in an adjustment to the Compensation Amount, Guaranteed Dividend and/or Put Amount, McKesson Deutschland GmbH & Co. KGaA ("McKesson Deutschland," formerly known as Dragonfly GmbH & Co. KGaA) would be required to make certain additional payments for any shortfall to all Celesio noncontrolling shareholders who previously received the Guaranteed Dividend, Compensation Amount and/or Put Amount. The Put Right specified in the Domination Agreement may be exercised until two months after the announcement regarding the end of the Appraisal Proceedings. In addition, if the Domination Agreement is terminated, the Put Right may be exercised for a two-month period after the date of termination. The exercise of the Put Right will reduce the balance of redeemable noncontrolling interests. There were no material exercises during the third quarter and first nine months of 2016. The balance of redeemable noncontrolling interests is reported at the greater of its carrying value or its maximum redemption value at each reporting date. The redemption value is the Put Amount adjusted for exchange rate fluctuations each period. At December 31, 2015 and March 31, 2015, the carrying value of redeemable noncontrolling interests of \$1.38 billion and \$1.39 billion exceeded the maximum redemption value of \$1.22 billion and \$1.21 billion. At December 31, 2015 and March 31, 2015, we owned approximately 76.0% of Celesio's outstanding common shares.

Changes in redeemable noncontrolling interests were as follows:

	Redeemable	
(In millions)	Noncontrolling	5
	Interests	
Balance, March 31, 2015	\$1,386	
Net income attributable to noncontrolling interests	34	
Other comprehensive income (loss)	(7)
Reclassification of recurring compensation to other accrued liabilities	(35)
Balance, December 31, 2015	\$1,378	
There were no material changes in our ownership interests with noncontrolling inte	rests during the third quarters	and

There were no material changes in our ownership interests with noncontrolling interests during the third quarters and first nine months of 2016 and 2015.

4. Divestiture of Businesses

During the second quarter of 2016, we sold our ZEE Medical business within our Distribution Solutions segment for a total purchase price of \$134 million and recorded a pre-tax gain of \$52 million (\$29 million after-tax) from this sale. During the first quarter of 2016, we also sold our nurse triage business within our Technology Solutions segment for net sale proceeds of \$84 million and recorded a pre-tax gain of \$51 million (\$38 million after-tax) from the sale. These divestitures did not meet the criteria to qualify as discontinued operations under the amended accounting guidance, which became effective for us in the first quarter of 2016. Accordingly, pre-tax gains from both divestitures were recorded in operating expenses within continuing operations of our condensed consolidated statements of operations. Pre and after-tax income of these businesses was not material for the quarters and nine months ended December 31, 2015 and 2014.

5. Discontinued Operations

During the fourth quarter of 2015, we committed to a plan to sell our Brazilian pharmaceutical distribution business and a small business from our Distribution Solutions segment. We acquired the Brazilian distribution business through our February 2014 acquisition of Celesio. The results of operations and cash flows of these businesses are classified as discontinued operations for all periods presented in our condensed consolidated financial statements.

During the fourth quarter of 2015, we recorded \$241 million of non-cash pre-tax (\$235 million after-tax) impairment charges to reduce the carrying value of this Brazilian distribution business to its estimated fair value, less costs to sell, based on our assessment at that time. The ultimate loss from the sale of this Brazilian distribution business may be different from our current assessment of the business' fair value. As a result, we may record additional loss upon the disposition of the business within discontinued operations.

During the first quarter of 2015, we decided to retain the workforce business within our International Technology business, which had been classified as a discontinued operation since the time we committed to a plan to sell the International Technology business in the first quarter of 2014. As a result, the workforce business was reclassified to continuing operations effective in the first quarter of 2015 for all periods presented and we recorded a non-cash pre-tax charge of \$34 million primarily in cost of sales relating to depreciation and amortization expense for the period in 2014 while the business was classified as held for sale. The workforce business, which provided workforce management solutions for the National Health Service in the United Kingdom, was transitioned to another service provider during the first quarter of 2016.

We completed the sale of a software business within our International Technology business during the second quarter of 2015 and at that time, we recorded a pre-tax and after-tax loss of \$6 million within the discontinued operations of our condensed consolidated statements of operations.

A summary of results of discontinued operations is as follows:

A summary of results of discontinued operations is as follows.	Ouarte	r Ended		Nine M	onths Ended
	-	ber 31,		Decemb	
(In millions)	2015	2014		2015	2014
Revenues	\$381	\$523		\$1,246	\$1,742
Cost of sales	(341) (479)	(1,123) (1,565)
Operating expenses	(36) (66)	(128) (214)
Other income (loss), net	(7) (4)	(21) (10)
Pre-tax loss from discontinued operations	(3) (26)	(26) (47)
Loss on sale					(6)
Income tax benefit	8	16		15	21
Loss from discontinued operations, net of tax	\$5	\$(10)	\$(11) \$(32)
A summary of carrying amounts of major classes of assets and liab	ilities inclu	uded as part	of di	scontinue	d operations is
as follows:					

	December 31,	March 31,
(In millions)	2015	2015
Receivables, net	\$255	\$314
Inventories, net	241	254
Other assets	86	92
Total assets of discontinued operations ⁽¹⁾	582	660
Drafts and account payable	247	209
Short-term borrowings	100	126
Other liabilities	248	328
Total liabilities of discontinued operations ⁽¹⁾	\$595	\$663
(1) Assets and liabilities of discontinued operations are included under the capt	ions "Prenaid expenses	s and other" and

(1) Assets and liabilities of discontinued operations are included under the captions "Prepaid expenses and other" and "Other accrued liabilities" within our condensed consolidated balance sheets.

12

6. Income Taxes

During the third quarters of 2016 and 2015, income tax expense related to continuing operations was \$204 million and \$198 million and included a net discrete tax benefit of \$16 million and a net discrete tax expense of \$4 million. During the first nine months of 2016 and 2015, income tax expense related to continuing operations was \$704 million and \$606 million and included net discrete tax benefits of \$45 million and \$14 million. Our reported income tax rates for the third quarters of 2016 and 2015 were 24.1% and 27.5% and for the first nine months of 2016 and 2015 were 27.3% and 29.7%. The fluctuations in our reported income tax rates are primarily due to changes within our business mix, including varying proportions of income attributable to foreign countries that have lower income tax rates and discrete items.

During the third quarter of 2016, we recognized a \$19 million discrete tax benefit due to a reduction in our deferred tax liabilities as a result of enacted tax law changes in certain foreign jurisdictions. During the second quarter of 2016, we evaluated the U.S. Tax Court's decision in Altera Corp. v. Commissioner related to the treatment of stock-based compensation expense in an intercompany cost-sharing agreement and recognized a discrete tax benefit of \$25 million based on our historical tax filing position.

As of December 31, 2015, we had \$564 million of unrecognized tax benefits, of which \$392 million would reduce income tax expense and the effective tax rate, if recognized. During the next twelve months, it is reasonably possible that audit resolutions and the expiration of statutes of limitations could potentially reduce our unrecognized tax benefits by up to \$123 million. However, this amount may change as we continue to have ongoing negotiations with various taxing authorities throughout the year.

We report interest and penalties on tax deficiencies as income tax expense. We recognized income tax expense of \$3 million and \$5 million during the third quarters of 2016 and 2015 and income tax expense of \$9 million and \$12 million during the first nine months of 2016 and 2015, before any tax benefit, related to interest and penalties in our condensed consolidated statements of operations. At December 31, 2015, before any tax benefits, our accrued interest and penalties on unrecognized tax benefits amounted to \$78 million.

We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. The IRS is currently examining our U.S. corporation income tax returns for years 2007 through 2009 and may issue a Revenue Agent Report before the end of our fiscal year 2016.

We previously received reassessments from the Canada Revenue Agency ("CRA") related to a transfer pricing matter impacting years 2003 through 2010. During the third quarter of 2014, the Tax Court of Canada dismissed our appeal of the 2003 reassessment and we filed a Notice of Appeal to the Federal Court of Appeal. During the first quarter of 2016, we reached an agreement to settle the transfer pricing matter for years 2003 through 2010 and recorded a discrete income tax benefit of \$12 million for a previously unrecognized tax benefit. The CRA is currently examining our Canadian income tax returns for years 2011 through 2013.

7. Earnings Per Common Share

Basic earnings per common share are computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share are computed similar to basic earnings per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

The computations for basic and diluted earnings per common share are as follows:

	Quarter Ended December 31,			Nine Months Ended December 31,				
(In millions, except per share amounts)	2015 2014							
Income from continuing operations	\$642	\$521		\$1,877		\$1,431		
Net income attributable to noncontrolling interests) (39)	(39)	(55)	
Income from continuing operations attributable to McKesson	629	482		1,838		1,376		
Income (Loss) from discontinued operations, net of tax	5	(10)	(11)	(32)	
Net income attributable to McKesson	\$634	\$472		\$1,827		\$1,344		
Weighted average common shares outstanding:								
Basic	230	232		231		232		
Effect of dilutive securities:								
Options to purchase common stock	1	2		1		1		
Restricted stock units	1	2		2		2		
Diluted	232	236		234		235		
Earnings (loss) per common share attributable to McKesson: ⁽¹⁾								
Diluted								
Continuing operations	\$2.71	\$2.04		\$7.86		\$5.85		
Discontinued operations	0.02	(0.04)	(0.05)	(0.13)	
Total	\$2.73	\$2.00		\$7.81		\$5.72		
Basic								
Continuing operations	\$2.74	\$2.07		\$7.95		\$5.94		
Discontinued operations	0.02	(0.04)	(0.04)	(0.14)	
Total	\$2.76	\$2.03		\$7.91		\$5.80		

(1)Certain computations may reflect rounding adjustments.

Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based and other restricted stock units. Approximately 1 million and nil potentially dilutive securities were excluded from the computations of diluted net earnings per common share for each of the quarters ended December 31, 2015 and 2014 and 1 million and 2 million potentially dilutive securities were excluded from the computations of diluted net earnings per common share for the nine months ended December 31, 2015 and 2014, as they were anti-dilutive.

8. Goodwill and Intangible Assets, Net

Changes in the carrying amount of goodwill were as follows:

(In millions)	Distribution Solutions	Technology Solutions	Total	
Balance, March 31, 2015	\$7,994	\$1,823	\$9,817	
Goodwill acquired	15		15	
Acquisition accounting and other adjustments	8		8	
Goodwill disposed	(59) (26) (85)
Foreign currency translation adjustments, net	(49) (5) (54)
Balance, December 31, 2015	\$7,909	\$1,792	\$9,701	

As of December 31, 2015 and March 31, 2015, the accumulated goodwill impairment losses were \$36 million in our Technology Solutions segment.

Information regarding intangible assets is as follows:

internation regarding many	December 31, Weighted				March 31,	2015
(Dollars in millions)	Average Remaining Amortization Period (years)	Gross Carrying Amount	Accumulated Amortization	Carrying	Gross Carrying Amount	Accumulated Amortization Net Carrying Amount
Customer lists	8	\$2,663	\$ (1,295)	\$1,368	\$2,683	\$(1,116) \$1,567
Service agreements	15	943	(251)	692	957	(215) 742
Pharmacy licenses	25	884	(111)	773	874	(65) 809
Trademarks and trade names	5 14	300	(90)	210	315	(82) 233
Technology	2	209	(193)	16	213	(184) 29
Other	3	163	(119)	44	162	(101) 61
Total		\$5,162	\$ (2,059)	\$3,103	\$5,204	\$ (1,763) \$3,441

Amortization expense of intangible assets was \$108 million and \$329 million for the quarter and nine months ended December 31, 2015 and \$125 million and \$384 million for the quarter and nine months ended December 31, 2014. Estimated annual amortization expense of these assets is as follows: \$86 million, \$378 million, \$360 million, \$327 million and \$302 million for the remainder of 2016 and each of the succeeding years through 2020 and \$1,651 million thereafter. All intangible assets were subject to amortization as of December 31, 2015 and March 31, 2015.

9. Debt and Financing Activities

Long-Term Debt

Our long-term debt includes both U.S. dollar and foreign currency (primarily Euro) denominated borrowings. At December 31, 2015 and March 31, 2015, \$8,711 million and \$9,709 million of total long-term debt were outstanding, of which \$996 million and \$1,529 million were included under the caption "Current portion of long-term debt" within the condensed consolidated balance sheets.

At March 31, 2015, we had a term loan with an outstanding balance of \$89 million (or £60 million). During the first quarter of 2016, we repaid this term loan for \$93 million. During the second quarter of 2016, we repaid our \$400 million floating rate notes due September 10, 2015 at maturity. During the third quarter of 2016, we repaid our \$500 million 0.95% notes due December 4, 2015 at maturity.

Revolving Credit Facilities

We had a syndicated \$1.3 billion five-year senior unsecured revolving credit facility, which was to expire in September 2016. We also had a syndicated €500 million five-year senior unsecured revolving credit facility, which was to expire in February 2018. Both revolving credit facilities were terminated in connection with the execution of a new \$3.5 billion revolving credit facility in October 2015, as discussed below. There were no borrowings under these facilities during the first nine months of 2016 and 2015. As of March 31, 2015, there were no amounts outstanding under these facilities.

During the third quarter of 2016, we entered into a syndicated \$3.5 billion five-year senior unsecured revolving credit facility (the "Global Facility"). The Global Facility has a \$3.15 billion aggregate sublimit of availability in Canadian dollars, British pounds sterling and Euros. The remaining terms and conditions of the Global Facility are substantially similar to those previously in place under the \$1.3 billion revolving credit facility which was terminated in October 2015. There were no borrowings outstanding under this facility during the third quarter of 2016, and as of December 31, 2015.

The Global Facility contains a financial covenant which obligates the Company to maintain a debt to capital ratio of no greater than 65% and other customary investment grade covenants. If we do not comply with these covenants, our ability to use the Global Facility may be suspended and repayment of any outstanding balances under the Global Facility may be required. At December 31, 2015, we were in compliance with all covenants.

We also maintain bilateral credit lines primarily denominated in Euros with a total committed and uncommitted balance of \$1.1 billion. During the first nine months of 2016 and 2015, we borrowed \$631 million and \$222 million and repaid \$633 million and \$181 million under these credit lines primarily related to short-term borrowings. These credit lines have interest rates ranging from 0.18% to 6%. As of December 31, 2015 and March 31, 2015, there were \$29 million and \$29 million outstanding under these credit lines.

Accounts Receivable Facilities

In connection with the execution of the Global Facility, we also terminated an accounts receivable sales facility (the "AR Facility") with a committed balance of \$1.35 billion during the third quarter of 2016. There were no borrowings outstanding under the AR Facility during the first nine months of 2016 (prior to the date of termination) and 2015, and as of March 31, 2015. The AR Facility contained requirements relating to the performance of the accounts receivable and covenants relating to the Company. If we did not comply with these covenants, our ability to use the AR Facility would have been suspended and repayment of any outstanding balances under the AR Facility would have been required. At March 31, 2015, we were in compliance with all covenants.

We also have accounts receivable factoring facilities (the "Factoring Facilities") denominated in foreign currencies with a total committed balance of \$6 million. During the first nine months of 2016 and 2015, we borrowed \$901 million and \$2,200 million and repaid \$1,037 million and \$2,154 million in short-term borrowings under these facilities. At December 31, 2015 and March 31, 2015, there were \$6 million and \$135 million in secured borrowings outstanding under these facilities. The Factoring Facilities will expire through April 2016.

Commercial Paper

We maintain a commercial paper program to support our working capital requirements and for other general corporate purposes. In November 2015, we replaced the existing program with a new commercial paper program through which the Company can issue up to \$3.5 billion in outstanding notes. We had no outstanding obligations under either program during the nine months ended December 31, 2015 and 2014, and as of December 31, 2015 and March 31, 2015.

10. Pension Benefits

The net periodic expense for our defined pension benefit plans is as follows:

	U.S. Plans				Non-U.S. Plans			U.S. Plans				Non-U.S. Plans				
	Quarter 1	arter Ended			Quarter Ended			Nine Months Ended				Nine Months Ended				
	Decembe	er í	31,		December 31,				December 31,				December 31,			
(In millions)	2015		2014		2015		2014		2015		2014		2015		2014	
Service cost - benefits earned during the year	\$1		\$—		\$4		\$4		\$3		\$1		\$14		\$13	
Interest cost on projected benefit obligation	4		5		6		8		13		14		18		26	
Expected return on assets	(5)	(5)	(7)	(8)	(14)	(16)	(23)	(23)
Amortization of unrecognized actuarial loss and prior service costs	11		5		1		1		32		15		3		3	
Curtailment loss (gain)							5			-			_		5	
Net periodic pension expense	\$11		\$5		\$4		\$10		\$34		\$14		\$12		\$24	

Cash contributions to these plans were \$8 million and \$35 million for the third quarters of 2016 and 2015, and \$52 million and \$65 million for the first nine months of 2016 and 2015. The projected unit credit method is utilized in measuring net periodic pension expense over the employees' service life for the pension plans. Unrecognized actuarial losses exceeding 10% of the greater of the projected benefit obligation or the market value of assets are amortized straight-line over the average remaining future service periods and expected life expectancy.

11. Hedging Activities

In the normal course of business, we are exposed to interest rate changes and foreign currency fluctuations. At times, we limit these risks through the use of derivatives such as interest rate swaps and forward foreign exchange contracts. In accordance with our policy, derivatives are only used for hedging purposes. We do not use derivatives for trading or speculative purposes.

Foreign currency rate risk

We conduct our business worldwide in U.S. dollars and the functional currencies of our foreign subsidiaries, including Euro, British pounds and Canadian dollars. Changes in foreign exchange rates will affect our results of operations, assets and liabilities, capital ratios and purchasing activities that are reported in U.S. dollars. We have certain foreign currency rate risk programs that manage the impact of foreign currency fluctuations primarily through the use of foreign currency forward-exchange contracts. These contracts are typically used to offset the potential earnings effects from intercompany foreign currency loans. These programs reduce but do not entirely eliminate foreign currency rate risk.

<u>Table of Contents</u> McKESSON CORPORATION FINANCIAL NOTES (CONTINUED) (UNAUDITED)

At December 31, 2015 and March 31, 2015, forward contracts to hedge the U.S. dollar against cash flows denominated in Canadian dollars with total notional values of \$399 million were designated for hedge accounting. These contracts will mature between March 2016 and March 2020. Changes in the fair values of contracts designated for hedge accounting are recorded into accumulated other comprehensive income and reclassified into earnings in the same period in which the hedged transaction affects earnings; amounts recorded to earnings for these contracts were not material during the quarters and nine months ended December 31, 2015 and 2014.

We also have a number of forward contracts to primarily hedge the Euro against cash flows denominated in British pounds and other European currencies. At December 31, 2015 and March 31, 2015, the total notional value of these contracts was \$1,878 million and \$1,755 million. These contracts will mature through June 2016 and none of these contracts were designated for hedge accounting. Changes in the fair values of contracts not designated for hedge accounting are recorded directly into earnings and accordingly, net losses of \$24 million and \$2 million for the third quarter and first nine months of 2016 and net losses of \$24 million and \$74 million for the third quarter and first nine months of 2015 were recorded within operating expenses. However, the gains and losses from these contracts are largely offset by changes in the value of the underlying intercompany foreign currency loans. Information regarding the fair value of derivatives on a gross basis is as follows:

0 0		0						
		December	r 31, 2015		March 31			
	Balance Sheet	Fair Valu	e of	U.S.	Fair Valu	U.S Dollar		
	Caption	Derivativ	e	Dollar	Derivativ	Notional		
(In millions)		Asset	Liability	Notional	Asset	Liability	Notional	
Derivatives designated for								
hedge accounting								
Foreign exchange contracts	Prepaid expenses	\$19	\$—	\$76	\$14	\$—	\$76	
(current)	and other							
Foreign exchange contracts (non-current)	Other assets	75		323	53		323	
Total		\$94	\$ —		\$67	\$ —		
Derivatives not designated for								
hedge accounting								
Foreign exchange contracts (current)	Prepaid expenses and other	\$25	\$—	\$1,162	\$7	\$—	\$493	
Foreign exchange contracts	Other accrued liabilities		10	716		79	1,262	
(current)	naonnues	¢ 05	¢10		ф 7	¢ 70		
Total		\$25	\$10		\$7	\$79 6 · · · 1		

Refer to Financial Note 12, "Fair Value Measurements," for more information on these recurring fair value measurements.

12. Fair Value Measurements

At December 31, 2015 and March 31, 2015, the carrying amounts of cash, certain cash equivalents, restricted cash, marketable securities, receivables, drafts and accounts payable, short-term borrowings and other current liabilities approximated their estimated fair values because of the short maturity of these financial instruments. Our long-term debt is carried at amortized cost. The carrying amounts and estimated fair values of these liabilities were \$8.7 billion and \$9.0 billion at December 31, 2015 and \$9.7 billion and \$10.4 billion at March 31, 2015. The estimated fair value of our long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.

Included in cash and cash equivalents at December 31, 2015 and March 31, 2015 were investments in money market funds and time deposits of \$1.9 billion and \$4.2 billion, which are reported at fair value. The fair value of these investments was determined by using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.

Fair values of our forward foreign currency derivatives were determined using quoted market prices of similar instruments in an active market and other observable inputs from available market information. These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 11, "Hedging Activities," for more information on our forward foreign currency derivatives.

There were no transfers between Level 1, Level 2 or Level 3 of the fair value hierarchy during the quarters and nine months ended December 31, 2015 and 2014.

13. Commitments and Contingent Liabilities

In addition to commitments and obligations in the ordinary course of business, we are subject to various claims, other pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. As described below, many of these proceedings are at preliminary stages and many seek an indeterminate amount of damages.

When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the ultimate loss. However, the likelihood of a loss with respect to a particular contingency is often difficult to predict and determining a meaningful estimate of the loss or a range of loss may not be practicable based on the information available and the potential effect of future events and decisions by third parties that will determine the ultimate resolution of the contingency. Moreover, it is not uncommon for such matters to be resolved over many years, during which time relevant developments and new information must be reevaluated at least quarterly to determine both the likelihood of potential loss and whether it is possible to reasonably estimate a range of possible loss. When a loss is probable but a reasonable estimate cannot be made, disclosure of the proceeding is provided. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. As discussed above, development of a meaningful estimate of loss or a range of potential loss is complex when the outcome is directly dependent on negotiations with or decisions by third parties, such as regulatory agencies, the court system and other interested parties. Such factors bear directly on whether it is possible to reasonably estimate a range of potential loss and boundaries of high and low estimates.

Significant developments in previously reported proceedings and in other litigation and claims, since the filing of our 2015 Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the periods ended June 30, 2015 and September 30, 2015, are set out below. Unless otherwise stated, we are currently unable to estimate a range of reasonably possible losses for the unresolved proceedings described below. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our financial position or results of operations.

Litigation, Government Subpoenas and Investigations

On August 29, 2007, PSKW, LLC filed a lawsuit against McKesson Specialty Arizona Inc. in the New York Supreme Court, New York County, alleging that McKesson Specialty Arizona misappropriated trade secrets and confidential information in launching its LoyaltyScript® program, PSKW, LLC v. McKesson Specialty Arizona Inc., Index No. 602921/07. The trial began on June 22, 2015 and has concluded. Post trial briefs will be filed, with a verdict to follow.

In May 2013, True Health Chiropractic, Inc. filed a class action against McKesson Corporation, claiming that McKesson sent unsolicited marketing faxes in violation of the Telephone Consumer Protection Act of 1991 ("TCPA"), as amended by the Junk Fax Protection Act of 2005 or JFPA. The case is pending in the Northern District of California. True Health Chiropractic Inc., et al. v. McKesson Corporation, et al., CV-13-02219 (HG). In August 2015, McKesson was granted a waiver from the opt out requirement from the Federal Communications Commission. Plaintiffs have appealed that decision. In September 2015, plaintiffs filed for class certification. The Court's ruling on that motion is pending.

On January 8, 2016, the state of West Virginia filed suit against the Company in state court in Boone County, West Virginia, State of West Virginia ex rel. Patrick Morrisey, Attorney General v. McKesson Corporation, Case No. 16-C-1. As with similar suits pending against other distributors, the lawsuit alleges violations of the West Virginia Controlled Substances Act, the West Virginia Consumer Credit and Protection Act, as well as common law claims for negligence, public nuisance and unjust enrichment, related to McKesson's supply of controlled substances to West Virginia from 2007-2012, and its alleged failure to report suspicious controlled substances orders.

As previously disclosed, on May 21, 2014, four hedge funds managed by Magnetar Capital filed a complaint against McKesson Deutschland GmbH & Co. KGaA (formerly known as "Dragonfly GmbH & Co KGaA"), a wholly-owned subsidiary of the Company, in a German court in Frankfurt, Germany, alleging that McKesson Deutschland violated German takeover law in connection with the Company's acquisition of Celesio by paying more to some holders of Celesio's convertible bonds than it paid to the shareholders of Celesio's stock, Magnetar Capital Master Fund Ltd. et al. v. Dragonfly GmbH & Co KGaA, No. 3- 05 O 44/14. On December 5, 2014, the court dismissed Magnetar's lawsuit. Magnetar subsequently appealed that ruling. On January 19, 2016, the appellate court issued a ruling reversing the lower court's decision. The Company plans to appeal.

From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests also can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements. Examples of such subpoenas and investigations are included in the Company's 2015 Annual Report on Form 10-K. The Company continues to receive and respond to these requests.

Value Added Tax Assessments

We operate in various countries outside the United States which collect value added taxes ("VAT"). The determination of the manner in which a VAT applies to our foreign operations is subject to varying interpretations arising from the complex nature of the tax laws. We have received assessments for VAT which are in various stages of appeal. We

disagree with these assessments and believe that we have strong legal arguments to defend our tax positions. Certain VAT assessments relate to years covered by an indemnification agreement. Due to the complex nature of the tax laws, it is not possible to estimate the outcome of these matters. However, based on the currently available information, we believe the ultimate outcome of these matters will not have a material adverse effect on our financial position, cash flows or results of operations.

14. Stockholders' Equity

Each share of the Company's outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to share equally in any dividends declared by the Company's Board of Directors (the "Board"). In July 2015, the Company's quarterly dividend was raised from \$0.24 to \$0.28 per common share for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements and other factors.

In May 2015, the Board authorized the repurchase of up to \$500 million of the Company's common stock. During the second quarter of 2016, we bought 2.5 million shares at an average price per share of \$196.20. At September 30, 2015, no authorized amounts were available for future repurchases of the Company's common stock under the May 2015 share purchase plan. In October 2015, the Board authorized the repurchase of up to \$2 billion of the Company's common stock. During the third quarter of 2016, we bought 1.9 million shares at an average price per share of \$186.99. During 2016, our share repurchases were completed through open market transactions. The total authorization outstanding for repurchases of the Company's common stock was \$1.6 billion at December 31, 2015. During the third quarter of 2016, we retired 115.5 million or \$7.8 billion of the Company's treasury shares previously repurchased. Under the applicable state law, these shares resume the status of authorized and unissued shares upon retirement. In accordance with our accounting policy, we allocate any excess of share repurchase price over par value between additional paid-in capital and retained earnings. Accordingly, our retained earnings and additional paid-in capital were reduced by \$6.3 billion during the third quarter of 2016.

Other Comprehensive Income (Loss)

Information regarding other comprehensive income (loss) including noncontrolling and redeemable noncontrolling interests, net of tax, by component is as follows:

	Quarter E		Nine Months Ended					
	December 31,			December 2		31,		
(In millions)	2015	2014		2015		2014		
Foreign currency translation adjustments ⁽¹⁾								
Foreign currency translation adjustments arising during period, net of income tax benefit of 3 , nil, 3 and nil (2) (3)	\$(246	\$(416)	\$(142)	\$(985)	
Reclassified to income statement, net of income tax expense of nil, nil, nil and nil ⁽⁴⁾	·	_				(10)	
	(246) (416)	(142)	(995)	
Unrealized gains (losses) on cash flow hedges Unrealized gains (losses) on cash flow hedges arising during period, net of income tax expense of nil, nil, nil and nil	(1) 1		5		(1)	
Changes in retirement-related benefit plans Net actuarial gain (loss) and prior service cost arising during the period, net of income tax benefit of nil, \$6, \$9 and \$6 ⁽⁵⁾	_	(21)	(28)	(21)	
Amortization of actuarial loss and prior service costs, net of income tax expense of 4 , 2 , 13 and 5 ⁽⁶⁾	^x 8	3		23		9		
Foreign currency translation adjustments, net of income tax expense of nil, nil, nil and nil	^f 7	2		3		4		
	15	(16)	(2)	(8)	

\$(232) \$(431) Other comprehensive income (loss), net of tax) \$(139) \$(1,004) Foreign currency translation adjustments result from the conversion of non-U.S. dollar financial statements of our (1) foreign subsidiaries into the Company's reporting currency, U.S. dollars, and were primarily related to our foreign subsidiary, Celesio, in 2016 and 2015.

The net foreign currency translation losses during the third quarter of 2016 were primarily due to the weakening of the Euro, British pound sterling and Canadian dollar against the U.S. dollar from October 1, 2015 to December 31, 2015 . The net foreign currency translation losses during first nine months of 2016 were primarily due to the $^{(2)}$

- weakening of the Canadian dollar against the U.S. dollar from April 1, 2015 to December 31, 2015. During the third quarter and first nine months of 2015, the currency translation losses were primarily due to the weakening of the Euro and British pound sterling against the U.S. dollar from April 1, 2014 to December 31, 2014. The third quarter and first nine months of 2016 include net foreign currency translation losses of \$32 million and
- (3) \$2 million, which are primarily attributable to redeemable noncontrolling interests. The third quarter and first nine months of 2015 included net foreign currency translation losses of \$13 million and \$164 million attributable to
- noncontrolling interests and translation losses of \$39 million attributable to redeemable noncontrolling interests. These net foreign currency losses were reclassified from accumulated other comprehensive income (loss) to (4) discontinued comprehensive income (loss) to
- discontinued operations within our consolidated statement of operations due to the sales of certain businesses. The third quarter and first nine months of 2016 include net actuarial gains of \$1 million and losses of \$5 million (5) attributable to redevent the redevent to the safety of \$1 million and losses of \$5 million (5) attributable to redevent to the safety of \$1 million and losses of \$5 million (5) attributable to redevent to the safety of \$1 million and losses of \$5 million (5) attributable to redevent to the safety of \$1 million and losses of \$5 million (5) attributable to redevent to the safety of \$1 million and losses of \$5 million (5) attributable to redevent to the safety of \$1 million and losses of \$5 million (5) attributable to redevent to the safety of \$1 million and losses of \$1 million attributable to redevent to the safety of \$1 million and losses of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to redevent to the safety of \$1 million attributable to the safety of \$1 mill
- attributable to redeemable noncontrolling interests.
- (6)Pre-tax amount reclassified into cost of sales and operating expenses in our condensed consolidated statements of operations. The related tax expense was reclassified into income tax expense in our condensed consolidated

statements of operations.

Accumulated Other Comprehensive Income (Loss)

Information regarding changes in our accumulated other comprehensive income (loss), net of tax, by component for the third quarter and first nine months of 2016 is as follows:

(In millions)	Foreign Currency Translation Adjustments, Net of Tax		Unrealized Gains (Losses on Cash Flow Hedges, Net of Tax	·	Unrealized Ne Gains (Losses and Other Components of Benefit Plans, Net of Tax	s) of	Total Accumulated Other Comprehensive Income (Loss)	e	
Balance at September 30, 2015	\$(1,346)	\$(15)	\$(283)	\$(1,644)	
Other comprehensive income (loss) before reclassifications	(246)	(1)	_		(247)	
Amounts reclassified to earnings and other	: —				15		15		
Other comprehensive income (loss) Less: amounts attributable to	(246)	(1)	15		(232)	
noncontrolling and redeemable noncontrolling interests	(32)			1		(31)	
Other comprehensive income (loss) attributable to McKesson	(214)	(1)	14		(201)	
Balance at December 31, 2015	\$(1,560)	\$(16)	\$(269)	\$(1,845)	
Balance at March 31, 2015	\$(1,420)	\$(21)	\$(272)	\$(1,713)	
Other comprehensive income (loss) before reclassifications	(142)	5		(28)	(165)	
Amounts reclassified to earnings and other	:				26		26		
Other comprehensive income (loss)	(142)	5		(2)	(139)	
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests	^{ng} (2)			(5)	(7)	
Other comprehensive income (loss) attributable to McKesson	(140)	5		3		(132)	
Balance at December 31, 2015	\$(1,560)	\$(16)	\$(269)	\$(1,845)	

15. Segment Information

We report our operations in two operating segments: McKesson Distribution Solutions and McKesson Technology Solutions. The factors for determining the reportable segments included the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. We evaluate the performance of our operating segments on a number of measures, including operating profit before interest expense, income taxes and results from discontinued operations.

Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows:

	Quarter E		Nine Mont December		
(In millions)	2015	2014	2015	2014	
Revenues					
Distribution Solutions ⁽¹⁾					
North America pharmaceutical distribution and services	\$39,615	\$37,397	\$119,750	\$106,848	
International pharmaceutical distribution and services	6,022	6,767	17,726	20,506	
Medical-Surgical distribution and services	1,568	1,565	4,579	4,473	
Total Distribution Solutions	47,205	45,729	142,055	131,827	
Technology Solutions - products and services	694	755	2,151	2,293	
Total Revenues	\$47,899	\$46,484	\$144,206	\$134,120	
Operating profit					
Distribution Solutions ⁽²⁾	\$906	\$803	\$2,742	\$2,333	
Technology Solutions ⁽³⁾	122	112	426	305	
Total	1,028	915	3,168	2,638	
Corporate Expenses, Net	(95) (103)	(320)	(317)	
Interest Expense	(87) (93)	(267)	(284)	
Income from Continuing Operations Before Income Taxes	\$846	\$719	\$2,581	\$2,037	

(1)Revenues derived from services represent less than 2% of this segment's total revenues.

Distribution Solutions operating profit for the third quarter and first nine months of 2016 include \$33 million and \$215 million in pre-tax charges related to our last-in, first-out ("LIFO") method of accounting for inventories. The third quarter and first nine months of 2015 include pre-tax LIFO charges of \$95 million and \$287 million. LIFO expense for the third quarter of 2016 includes a gross charge of \$65 million, partially offset by a \$32 million

(2) reversal of a portion of the LIFO expense recorded in the first half of 2016 due to a change in estimate. LIFO expense was less in 2016 primarily due to lower full year expectations for price increases. The third quarter and first nine months of 2016 include \$17 million and \$76 million of net cash proceeds representing our share of net settlements of antitrust class action lawsuits against drug manufacturers. Additionally, the first nine months of 2016 include a pre-tax gain of \$52 million recognized from the sale of our ZEE Medical business. Technology Solutions operating profit for the first nine months of 2016 includes a pre-tax gain of \$51 million

(3) recognized from the sale of our nurse triage business, and for the first nine months of 2015 includes a non-cash pre-tax charge of \$34 million related to the retained workforce business within our International Technology business.

Table of Contents McKESSON CORPORATION FINANCIAL REVIEW (CONTINUED) (UNAUDITED)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

GENERAL

Management's discussion and analysis of financial condition and results of operations, referred to as the Financial Review, is intended to assist the reader in the understanding and assessment of significant changes and trends related to the results of operations and financial position of the Company together with its subsidiaries. This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying financial notes in Item 1 of Part I of this Quarterly Report on Form 10-Q and in Item 8 of Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2015 previously filed with the SEC on May 12, 2015 ("2015 Annual Report").

The Company's fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company's fiscal year.

Certain statements in this report constitute forward-looking statements. See "Factors Affecting Forward-Looking Statements" included in this Quarterly Report on Form 10-Q.

Results of Operations

Overview:

(Dollars in millions, except per share data)	Quarter E Decembe	Nine Months Ended December 31,								
(=,,)	2015	2014	Char	nge	2015		2014	Cha	nge	
Revenues	\$47,899	\$46,48		%	\$144,20)6	\$134,12		%	
Income from Continuing Operations Before Income Taxes	\$846	\$719	18	%	\$2,581		\$2,037	27	%	
Income Tax Expense	(204)	(198)3		(704)	(606)16		
Income from Continuing Operations	642	521	23		1,877		1,431	31		
Income (Loss) from Discontinued Operations, Net of Tax	5	(10)(150)	(11)	(32)(66)	
Net Income	647	511	27		1,866		1,399	33		
Net Income Attributable to Noncontrolling Interests	(13)	(39)(67)	(39)	(55)(29)	
Net Income Attributable to McKesson Corporation	\$634	\$472	34	%	\$1,827		\$1,344	36	%	
Diluted Earnings (Loss) Per Common Share Attributable to McKesson Corporation										
Continuing Operations	\$2.71	\$2.04	33	%	\$7.86		\$5.85	34	%	
Discontinued Operations	0.02	(0.04)(150)	(0.05)	(0.13)(62)	
Total	\$2.73	\$2.00	37	%	\$7.81		\$5.72	37	%	
Weighted Average Diluted Common Shares	232	236 6 increas	(2))%	234	nd te	235		%	

Revenues for the third quarter and first nine months of 2016 increased 3% and 8% compared to the same periods a year ago. Excluding unfavorable foreign currency effects of 2%, revenues increased 5% and 10% for the third quarter and first nine months of 2016 primarily due to market growth and expanded business with existing customers within our North America pharmaceutical distribution businesses.

Table of Contents McKESSON CORPORATION FINANCIAL REVIEW (CONTINUED) (UNAUDITED)

Income from continuing operations before income taxes for the third quarter and first nine months of 2016 increased 18% and 27% compared to the same periods a year ago primarily due to higher operating profit from both of our operating segments: Distribution Solutions and Technology Solutions. Additionally, income from continuing operations before income taxes was also affected by:

Last-in-first out ("LIFO") inventory charges of \$33 million and \$215 million for the third quarter and first nine months of 2016, compared to \$95 million and \$287 million for the same periods a year ago,

Pre-tax gains of \$103 million (after-tax \$67 million) resulting from the 2016 second quarter sale of our ZEE Medical business and the 2016 first quarter sale of our nurse triage business,

Acquisition-related expenses of \$23 million and \$86 million for the third quarter and first nine months of 2016, compared to \$51 million and \$162 million for the same periods a year ago. Decreases in these expenses are associated with the decline in integration activities for our 2014 and 2013 acquisitions of Celesio AG ("Celesio") and PSS World Medical Inc. ("PSSI"), and

\$17 million and \$76 million of pre-tax credits for the third quarter and first nine months of 2016 representing net cash proceeds for our share of antitrust legal settlements.

Income tax expense for the third quarter and first nine months of 2016 include a \$19 million tax benefit related to enacted tax law changes in foreign jurisdictions. Additionally, income tax expense for the first nine months of 2016 include a \$25 million discrete tax benefit recorded based on our assessment of a U.S. Tax Court decision made in July 2015.

Net income attributable to McKesson Corporation for the third quarters of 2016 and 2015 was \$634 million and \$472 million and for the first nine months of 2016 and 2015 was \$1,827 million and \$1,344 million. Diluted earnings per common share attributable to McKesson for the third quarters of 2016 and 2015 were \$2.73 and \$2.00 and for the first nine months of 2016 and 2015 were \$7.81 and \$5.72.

Revenues: